None
Quote | Telix Pharmaceuticals Ltd (OTCMKTS:TLPPF)
Last: | $13.075 |
---|---|
Change Percent: | -6.38% |
Open: | $13.44 |
Close: | $13.075 |
High: | $13.45 |
Low: | $12.95 |
Volume: | 3,883 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Telix Pharmaceuticals Ltd (OTCMKTS:TLPPF)
2024-06-18 13:48:58 ET Summary Telix Pharmaceuticals' product revenues in full-year 2023 were $502.5 million, which was an increase of 214% from 2022 with revenues of only $160.1 million. TLX591 + best SOC is being used to treat patients with metastatic castration-resistant prosta...
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the “Offering”) of 17,000,000 American Depositary Shares (...
Message Board Posts | Telix Pharmaceuticals Ltd (OTCMKTS:TLPPF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Telix Pharmaceuticals Ltd Company Name:
TLPPF Stock Symbol:
OTCMKTS Market:
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the “Offering”) of 17,000,000 American Depositary Shares (...
MELBOURNE, Australia, June 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational...
TLX591 is an investigational anti-PSMA 1 radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen. Reported median radiographic progression-free survival (rPFS) is 8.8 months. Builds on prior data from...